It’s Genius: Advances in Gene Therapy
Planned in cooperation with the ASHP Emerging Sciences SAG
ACPE Activity Number: 0204-0000-22-588-H01-P
Release Date: Oct 20, 2022
Expiration Date: Oct 20, 2025
Activity Type: Knowledge-based
CE Credits: 1.0 contact hour, (0.10 CEU)
Activity Fee: Member – Free / Non-Member – Not Available
This activity is a recording from a live webinar and those that claim credit for the live webinar should not claim credit for this activity.
Activity Overview
The purpose of this educational session is to describe nomenclature associated with emerging gene therapy development and administration. Place in therapy and clinical evidence for the safety and efficacy for the 2 FDA-approved products will be reviewed and assessed. New therapies in the development pipeline will be discussed. Finally, cost-effectiveness and payment models for gene therapy will be addressed.
Accreditation
The American Society of Health-System Pharmacists is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.
Target Audience
Learning Objectives
After completing this activity, the learner should be able to…
1. Discuss approved methods for the delivery of gene therapy treatments.
2. Describe the complexities of onasemongene abeprvovec-xioi (Zolgensma) and voretigene neparvovec-rzyl (Luxturna) administration to relevant stakeholders.
3. Identify key concepts pharmacy programs should consider when providing services for patients receiving gene therapy.
4. Describe implications of gene therapy on pharmacy practice and the health care industry.
Schedule of Activities
-
Introduction and Announcements
-
Presentation
-
Questions, Answers, and Discussion
Faculty
Assistant Director, Clinical Program Development
John Hopkins Home Care Group
Baltimore, MD
Deanna Moretz, PharmD, BCPS
Oregon State University College of Pharmacy
Portland, OR
Relevant Financial Relationship Disclosure
In accordance with our accreditor’s Standards of Integrity and Independence in Accredited Continuing Education, ASHP requires that all individuals in control of content disclose all financial relationships with ineligible companies. An individual has a relevant financial relationship if they have had a financial relationship with an ineligible company in any dollar amount in the past 24 months and the educational content that the individual controls is related to the business lines or products of the ineligible company.
An ineligible company is any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. The presence or absence of relevant financial relationships will be disclosed to the activity audience.
-
No one in control of the content of this activity has a relevant financial relationship (RFR) with an ineligible company.
Methods and CE Requirements
This activity consists of recordings of faculty slides presentations, active learning activities, discussion, and handouts. Participants must participate in the activity in its entirety to claim continuing pharmacy education credit online at ASHP Learning Center. Follow the prompts online to complete the evaluation, claim credit and view the statement of credit immediately after completing the activity.
Per ACPE requirements, CPE credit must be claimed within 60 days of being earned. Once you have processed and claimed your CE credit, we encourage you to check your NABP eProfile account to verify your credits were transferred successfully before the ACPE 60-day deadline. It is an electronic direct-report process so your credits should appear in your account within a few minutes. After the 60 day deadline, ASHP will no longer be able to report your credit(s) for this activity.